Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HK1 | P19367 | 1/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4617586 | 0.80 | CES1 (0.41) | SMN1; SMN2MAPTGAANOX1NR1H2 | |
| SCHEMBL7519169 | 0.76 | P2RX4 (0.45) | SMN1; SMN2MAPTGAANR1H2NR1H3 | |
| SCHEMBL4742835 | 0.76 | LMNA (0.47) | SMN1; SMN2MAPTGAAPOLBKMT2A | |
| Acetic Acid SCHEMBL27980670 | 0.76 | GAA (0.50) | SMN1; SMN2MAPTGAANR1H2NR1H3 | |
| SCHEMBL16706577 | 0.74 | SMN1; SMN2 (0.59) | SMN1; SMN2MAPTGAANOX1CES1 | |
| Biphenyl SCHEMBL29059196 | 0.73 | SMN1; SMN2 (0.67) | SMN1; SMN2MAPTGAACES1ALDH1A1 | |
| Biphenyl SCHEMBL15332958 | 0.73 | SMN1; SMN2 (0.67) | SMN1; SMN2MAPTGAACES1ALDH1A1 | |
| Biphenyl SCHEMBL538359 | 0.73 | SMN1; SMN2 (0.67) | SMN1; SMN2MAPTGAACES1ALDH1A1 | |
| Biphenyl SCHEMBL1822628 | 0.73 | SMN1; SMN2 (0.67) | SMN1; SMN2MAPTGAACES1ALDH1A1 | |
| SCHEMBL11409349 | 0.73 | BCHE (0.53) | SMN1; SMN2MAPTGAAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101427135-B | T cell assays | ANTITOPE LTD. (GB) | 2014-10-29 | — | — | CN | disclosed |
| EP-1989544-B1 | T CELL ASSAYS | ANTITOPE LTD (GB) | 2011-06-22 | — | — | EP | disclosed |
| US-20090221024-A1 | T CELL ASSAYS | ANTITOPE LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| CN-101427135-A | T cell assays | ANTITOPE LTD (GB) | 2009-05-06 | — | — | CN | disclosed |
| EP-1989544-A1 | T CELL ASSAYS | Antitope Limited (GB) | 2008-11-12 | — | — | EP | disclosed |
| US-20080255091-A1 | COMPOUNDS TO TREAT AMYLOIDOSIS AND PREVENT DEATH OF BETA-CELLS IN TYPE 2 DIABETES MELLITUS | ASTRUM THERAPEUTICS PTY LTD. (AU) | 2008-10-16 | — | — | US | disclosed |
| EP-1879564-A2 | COMPOUNDS TO TREAT AMYLOIDOSIS AND PREVENT DEATH OF BETA-CELLS IN TYPE 2 DIABETES MELLITUS | Astrum Therapeutics Pty, Ltd. (AU) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007099341-A1 | T CELL ASSAYS | ANTITOPE LIMITED (GB) | 2007-09-07 | — | — | WO | disclosed |
| US-20060252819-A1 | Compounds to treat amyloidosis and prevent death of beta-cells in type 2 diabetes mellitus | ASTRUM THERAPEUTICS PTY LTD (AU) | 2006-11-09 | — | — | US | disclosed |
| WO-2006110477-A2 | COMPOUNDS TO TREAT AMYLOIDOSIS AND PREVENT DEATH OF BETA-CELLS IN TYPE 2 DIABETES MELLITUS | ASTRUM THERAPEUTICS PTY. LTD. (AU) | 2006-10-19 | — | — | WO | disclosed |
| WO-1997038978-A1 | ANTICONVULSANT (10,11-DIHYDRO) 10-OXY-5H-DIBENZ[B,F]AZEPINE-5-CARBOXAMIDES | TRIFARMA S.R.L. (IT) | 1997-10-23 | — | — | WO | disclosed |
| US-4181655-A | ANTIDEPRESSANTS | RESEARCH INSTITUTE FOR MEDICINE AND CHEMISTRY INC. (US) | 1980-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255091-A1 | COMPOUNDS TO TREAT AMYLOIDOSIS AND PREVENT DEATH OF BETA-CELLS IN TYPE 2 DIABETES MELLITUS | IAPP, BCL2, AMY2A | SMN1; SMN2 387/4885MAPT 531/4885GAA 257/4885 |
| US-20060252819-A1 | Compounds to treat amyloidosis and prevent death of beta-cells in type 2 diabetes mellitus | IAPP, BCL2, AMY2A | SMN1; SMN2 387/4885MAPT 531/4885GAA 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.